Global Blood Therapeutics, Inc. (GBT)
| Market Cap | 1.81B |
| Revenue (ttm) | 148.73M |
| Net Income (ttm) | -249.46M |
| Shares Out | 62.10M |
| EPS (ttm) | -4.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $28.69 |
| Previous Close | $29.44 |
| Change ($) | -0.75 |
| Change (%) | -2.55% |
| Day's Open | 29.58 |
| Day's Range | 28.65 - 29.88 |
| Day's Volume | 1,160,409 |
| 52-Week Range | 28.65 - 72.79 |
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta ® (voxelotor) in Children with SCD Ages 4 to 11
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT's board of dire...
The pharmaceutical company, which specializes in therapies to fight sickle cell disease, rose nearly 8% on Wednesday.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT's board of dire...
New Oxbryta® (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease New Oxbryta® (voxelotor) Data fr...
Global Blood Therapeutics Inc (NASDAQ: GBT) reported a Q1 EPS loss of ($1.21) wider than the anticipated loss estimate of $1.01. Q1 sales of $39.04 million well below the consensus of $43.00 million, al...
The company reported disappointing sales for its sickle-cell disease drug.
Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.
Global Blood (GBT) delivered earnings and revenue surprises of -18.63% and -8.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Achieved Oxbryta ® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe
SOUTH SAN FRANCISCO, Calif. and HANOVER, Md., May 04, 2021 (GLOBE NEWSWIRE) -- In recognition of World Sickle Cell Day, which falls on June 19, 2021, Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) ...
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood Therapeutics Inc (NASDAQ: GBT) has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study evaluating Oxbryta (voxelotor) tablets in...
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of 72-week ...
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pursues a n...
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively in-li...
Grant proposals from community-based organizations and institutions accepted through April 23, 2021 Grant proposals from community-based organizations and institutions accepted through April 23, 2021
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, Ma...
Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.
Global Blood (GBT) delivered earnings and revenue surprises of -3.09% and 6.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Global Blood Therapeutics (NASDAQ:GBT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 37.11% over the past year to ($1.00...
Achieved Oxbryta ® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020
Global Blood Therapeutics (NASDAQ:GBT) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results...
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2021, the compensation committee of GBT's board of ...
Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation o...
Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price. The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.
Since 2017, GBT has come a long way to gain Oxbryta approval for treating sickle cell disease. After over 100% capital gains, the stock gave up some profits as the market is sizing up Oxbryta's sales pr...
Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in F irst H alf of 2021
Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and ...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual ...
GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide. It has been subjected to an unwarranted selloff due to a slower than expect...
Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. The post Global Blood Therapeutics News: 5 Things for GBT Stock Inve...
Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript
Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months of 2020
Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta ® ( voxelotor )
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on Thursday, N...
About GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT6... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Ted Love | Employees 389 |
| Stock Exchange NASDAQ | Ticker Symbol GBT |
Financial Performance
In 2020, GBT's revenue was $123.80 million, an increase of 5,773.01% compared to the previous year's $2.11 million. Losses were -$247.55 million, -7.20% less than in 2019.
Analyst Forecasts
According to 20 analysts, the average rating for GBT stock is "Buy." The 12-month stock price forecast is 78.47, which is an increase of 173.51% from the latest price.